Aaron Schutzer

Corporate Counsel (2013 – 2017) • Drafted and negotiated license agreements and merger and acquisition agreements to execute against corporate growth by acquisition goal, successful deals include IBT license to Emergent of technology for development of equine immunoglobulin therapeutics and Emergent acquisition of UV-4B program from United Therapeutics • Drafted and negotiated material transfer and sponsored research agreements to evaluate new technologies for pipeline growth • Drafted and negotiated confidentiality disclosure agreements to facilitate deal discussions • Drafted and negotiated Employee Matters Agreement governing successful spin-off of biosciences division Intellectual Property Counsel (2012 – 2017) • Prosecuted U.S. and rest of world patents directed to small molecules, methods of use thereof to neutralize chemical warfare agents, and antibacterial methods to procure necessary scope of patent protection to support business needs • Conducted intellectual property due diligence for license agreements and merger and acquisition agreements, successful deals including Emergent acquisition of Cangene Corp., Emergent acquisition of EV-035 series from Evolva Holding SA, and Emergent acquisition of Healthcare Protective Products Group from Bracco Diagnostics Inc. • Advised key decision makers on suitability of licenses, mergers, and acquisitions to ensure informed decision making • Responsible for training Seattle and Lansing bioscience and biodefense scientific personnel to identify new intellectual property for protection by patent or trade secret

• Conducted technical discovery review and drafted legal memoranda in support of life science and alternative energy intellectual property litigation

• Prosecuted U.S. and rest of world patents directed to proteins, antibodies, and methods of treating inflammatory diseases therewith

• Drafted and prosecuted U.S. and rest of world patents directed to proteins, antibodies, small molecule, medical device, mechanical, method of treatment, and alternative energy inventions for ZymoGenetics, Inc., Oregon Health Sciences University and various startup corporations • Named patent attorney on 13 U.S. Patents • Provided litigation support in streaming media security algorithm matter; responsibilities included technical discovery review and analysis of legal issues and damages; drafted numerous legal memoranda on trial issues

• Drafted and prosecuted U.S. and rest of world patents directed to proteins, antibodies, and methods of treating inflammatory diseases therewith; collaborated prosecution with counsel at Novo Nordisk A/S pursuant to license agreement therewith • Named patent attorney on 12 U.S. patents • Conducted freedom to operate and patentability analysis for protein, method of treatment, and chimeric antibody scientific research and counseled management and scientific staff on same • Drafted and negotiated collaborative research agreements for acquisition of intellectual property rights to key research molecules